Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Authors
Keywords
-
Journal
EClinicalMedicine
Volume 58, Issue -, Pages 101882
Publisher
Elsevier BV
Online
2023-03-21
DOI
10.1016/j.eclinm.2023.101882
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Effect of Orlistat on Sterol Metabolism in Obese Patients
- (2022) Yu-Jin Kwon et al. Frontiers in Endocrinology
- Obesity Prevalence Among U.S. Adults During the COVID-19 Pandemic
- (2022) Brandon J. Restrepo AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Long Term Weight Loss Diets and Obesity Indices: Results of a Network Meta-Analysis
- (2022) Jana Jabbour et al. Frontiers in Nutrition
- Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide
- (2022) Dimitrios Patoulias et al. AMERICAN JOURNAL OF CARDIOLOGY
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
- (2022) Yunfeng Yu et al. Frontiers in Cardiovascular Medicine
- Precision Medicine and Obesity
- (2021) Maria Daniela Hurtado A et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial
- (2021) Clare A. Whicher et al. DIABETES OBESITY & METABOLISM
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome
- (2021) Vian Ahmed Wasta Esmail et al. Arab Journal of Gastroenterology
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients with Lipodystrophy
- (2021) Andrew Grover et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis
- (2021) Xiang‐Guo Lei et al. Obesity
- Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses
- (2021) Andrei C. Sposito et al. Obesity Reviews
- Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice
- (2021) Muhammad Ishaq et al. Frontiers in Endocrinology
- The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
- (2021) Makoto Fukuda DIABETES
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight
- (2021) Roger S. McIntyre et al. JOURNAL OF AFFECTIVE DISORDERS
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity
- (2021) Esmeralda Capristo et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Longitudinal Trends in Body Mass Index Before and During the COVID-19 Pandemic Among Persons Aged 2–19 Years — United States, 2018–2020
- (2021) Samantha J. Lange et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Anti-obesity drug discovery: advances and challenges
- (2021) Timo D. Müller et al. NATURE REVIEWS DRUG DISCOVERY
- Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey
- (2021) Craig M. Hales et al. Obesity
- Amylin as a Future Obesity Treatment
- (2021) Babak Dehestani et al. Journal of Obesity & Metabolic Syndrome
- Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
- (2020) Igho J. Onakpoya et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- Lorcaserin Departs, Leaving More Questions than Answers
- (2020) Rekha Kumar et al. Obesity
- Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials
- (2020) Long Ge et al. BMJ-British Medical Journal
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the Global Burden of Disease Study
- (2020) Haijiang Dai et al. PLOS MEDICINE
- Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity
- (2020) Leo Sungwong Choi et al. INTERNATIONAL JOURNAL OF OBESITY
- Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials
- (2020) Harpreet S. Bajaj et al. DIABETES OBESITY & METABOLISM
- Factors affecting weight loss variability in obesity
- (2020) Robert Dent et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
- (2020) Leonardo Andrade Mesquita et al. Obesity Reviews
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
- (2020) Karine Clément et al. Lancet Diabetes & Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
- (2019) Xavier Pi-Sunyer et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of Liraglutide Plus Phentermine in Adults with Obesity Following 1 Year of Treatment by Liraglutide Alone: A Randomized Placebo-Controlled Pilot Trial
- (2019) Jena Shaw Tronieri et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
- (2019) Olivia M. Farr et al. DIABETES OBESITY & METABOLISM
- A randomized, placebo‐controlled crossover trial of phentermine‐topiramate ER in patients with binge‐eating disorder and bulimia nervosa
- (2019) Debra L. Safer et al. INTERNATIONAL JOURNAL OF EATING DISORDERS
- Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists
- (2019) Jeffrey I. Mechanick et al. Surgery for Obesity and Related Diseases
- Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
- (2019) Maddalena Grieco et al. Frontiers in Neuroscience
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
- (2019) Maria Mirabelli et al. International Journal of Environmental Research and Public Health
- Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults with Low Leptin Levels
- (2018) ALEX DEPAOLI et al. DIABETES
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- (2018) Mark Warren et al. DIABETES OBESITY & METABOLISM
- Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
- (2018) Gene-Jack Wang et al. INTERNATIONAL JOURNAL OF OBESITY
- Addressing Obesity in Aging Patients
- (2018) John A. Batsis et al. MEDICAL CLINICS OF NORTH AMERICA
- Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial
- (2018) Alessio Basolo et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
- (2018) Xuechan Lyu et al. Frontiers in Pharmacology
- Precision medicine: diagnosis and management of obesity
- (2018) Gema Frühbeck et al. Lancet Diabetes & Endocrinology
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke
- (2018) Subodh Verma et al. CIRCULATION
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- High Prevalence of Rare Monogenic Forms of Obesity in Obese Guadeloupean Afro-Caribbean Children
- (2017) Lydia Foucan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
- (2016) Jean L. Chan et al. CLINICAL ENDOCRINOLOGY
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- The Psychosocial Burden of Obesity
- (2016) David B. Sarwer et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients
- (2016) Hannah Mathew et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Leptin sensitizer reverses obesity
- (2016) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Management of Obesity in Women
- (2016) Nadia N. Ahmad et al. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
- (2015) Jennifer S. ten Kulve et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Leptin and the brain: Influences on brain development, cognitive functioning and psychiatric disorders
- (2015) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
- (2014) L. van Bloemendaal et al. DIABETES
- Identification and Saturable Nature of Signaling Pathways Induced by Metreleptin in Humans: Comparative Evaluation of In Vivo, Ex Vivo, and In Vitro Administration
- (2014) Hyun-Seuk Moon et al. DIABETES
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2014) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults
- (2014) Bradley C. Johnston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
- (2014) Sonja K. Billes et al. PHARMACOLOGICAL RESEARCH
- Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance
- (2014) H. Stegenga et al. BMJ-British Medical Journal
- 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: Implications and New Opportunities for Registered Dietitian Nutritionists
- (2014) Barbara E. Millen et al. Journal of the Academy of Nutrition and Dietetics
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues
- (2013) G-J Wang et al. INTERNATIONAL JOURNAL OF OBESITY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance
- (2011) H.-S. Moon et al. DIABETES
- Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr-/- Mice
- (2011) H. E. Bates et al. DIABETES
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
- (2011) E A Rabiner et al. MOLECULAR PSYCHIATRY
- Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity
- (2011) Brianna Gray et al. NUTRITION REVIEWS
- The Effect of Tesofensine on Appetite Sensations
- (2011) Jo-Anne Gilbert et al. Obesity
- Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24-Week Randomized, Placebo-Controlled, Multicenter Trial
- (2011) Steven R. Smith et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
- (2009) David J. Heal et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- (2009) C. Daousi et al. CLINICAL ENDOCRINOLOGY
- Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder
- (2009) L D Levy et al. INTERNATIONAL JOURNAL OF OBESITY
- Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States
- (2008) Jean L Chan et al. CLINICAL PHARMACOKINETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now